Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Photodiagnosis Photodyn Ther. 2018 Dec;24:185-191. doi: 10.1016/j.pdpdt.2018.09.006. Epub 2018 Sep 18.

Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer.

Author information

1
Department of Radiology, Fuwai Central China Cardiovascular Hospital, #1 Fuwai Road, Zhengzhou, Henan Province, 450000, China.
2
Department of Radiology, University of Pittsburgh, 100 Technology Drive, Pittsburgh, PA, 15219, USA.
3
Vanderbilt University Institute of Imaging Sciences, Nashville, TN, 37232, USA.
4
Department of Surgical Oncology and General Surgery, First Affiliated Hospital of China Medical University, Shenyang, 110001, China.
5
Department of Radiology, Fuwai Central China Cardiovascular Hospital, #1 Fuwai Road, Zhengzhou, Henan Province, 450000, China. Electronic address: cjr.geyinghui@vip.163.com.
6
Department of Radiology, University of Pittsburgh, 100 Technology Drive, Pittsburgh, PA, 15219, USA; Department of Medicine, University of Pittsburgh, 3501 Fifth Ave, Pittsburgh, PA, 15213, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15261, USA; University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15232, USA. Electronic address: mingfeng.bai@vanderbilt.edu.

Abstract

Triple negative breast cancer (TNBC) is the deadliest form of breast cancer because it is more aggressive, diagnosed at later stage and more likely to develop local and systemic recurrence. Many patients do not experience adequate tumor control after current clinical treatments involving surgical removal, chemotherapy and/or radiotherapy, leading to disease progression and significantly decreased quality of life. Here we report a new combinatory therapy strategy involving cannabinoid-based medicine and photodynamic therapy (PDT) for the treatment of TNBC. This combinatory therapy targets two proteins upregulated in TNBC: the cannabinoid CB2 receptor (CB2R, a G-protein coupled receptor) and translocator protein (TSPO, a mitochondria membrane receptor). We found that the combined CB2R agonist and TSPO-PDT treatment resulted in synergistic inhibition in TNBC cell and tumor growth. This combinatory therapy approach provides new opportunities to treat TNBC with high efficacy. In addition, this study provides new evidence on the therapeutic potential of CB2R agonists for cancer.

KEYWORDS:

Agonist; CB2 receptor; Cannabinoid; Combination therapy; Photodynamic therapy; Synergistic; Triple negative breast cancer

PMID:
30240926
PMCID:
PMC6289793
[Available on 2019-12-01]
DOI:
10.1016/j.pdpdt.2018.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center